April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Thiolated Chitosan for the Treatment of Dry Eye - Evaluation in the Botulinum Toxin-B Induced Dry Eye Mouse Model
Author Affiliations & Notes
  • T. Hongyok
    Ophthalmology, Wills Eye Institute, Philadelphia, Pennsylvania
  • M. Hornof
    Croma-Pharma, Leobendorf, Austria
  • J. M. Chae
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland
  • Y. J. Shin
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland
  • D. Na
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland
  • L. Li
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland
  • R. S. Chuck
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland
  • Footnotes
    Commercial Relationships  T. Hongyok, Croma-Pharma, R; M. Hornof, Croma-Pharma, E; J.M. Chae, None; Y.J. Shin, None; D. Na, None; L. Li, None; R.S. Chuck, Croma-Pharma, R.
  • Footnotes
    Support  Croma-Pharma
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 4654. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. Hongyok, M. Hornof, J. M. Chae, Y. J. Shin, D. Na, L. Li, R. S. Chuck; Thiolated Chitosan for the Treatment of Dry Eye - Evaluation in the Botulinum Toxin-B Induced Dry Eye Mouse Model. Invest. Ophthalmol. Vis. Sci. 2009;50(13):4654.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The role of a topically applied thiolated polymer, chitosan-N-acetylcysteine conjugate (C-NAC), was investigated in a dry eye mouse model. It is postulated that interaction between thiol groups of the C-NAC with cysteine-rich mucins (MUC5AC) increases tear film stability.

Methods: : Dry eye was induced by injecting botulinum toxin B (BTX-B) in the right eye lacrimal glands of CBA/J mice. Eye drops containing C-NAC 0.5%, C-NAC 0.3%, vehicle (control), artificial tear (Artelac® EDO®) or fluorometholone (FML®) were applied in a masked fashion to group A-E, respectively, twice per day starting from day 3 until 4 weeks after BTX-B injection. Corneal fluorescein staining was periodically recorded. Quantitative Real-Time RT-PCR and immunofluorescence staining were performed at the end of the study to evaluate expression of inflammatory cytokines in ocular surface tissues.

Results: : Mice treated with C-NAC 0.5% and fluorometholone showed a downward trend in corneal staining compared to the other 3 groups, which was not statistically significant. C-NAC formulations, fluorometholone and artificial tear significantly decreased IL-1β, IL-10, IL-12, and TNF- expression in ocular surface tissues in comparison to the control (Tab. 1).

Conclusions: : This study has demonstrated the potential usefulness of the BTX-B-induced dry eye mouse model to evaluate new dry eye treatment strategies. Evaluation of important molecular biomarkers of dry eye disease suggests that C-NAC may have some protective ocular surface properties. However, clinical data did not indicate statistically significant improvement of tear film stability in any of the groups tested.

Keywords: cornea: tears/tear film/dry eye • cytokines/chemokines • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×